Enzymes are nature's engine for many processes. Diving into the stability and function of enzymes will give us a better understanding of these processes.
In this webinar, you will learn:
37:25When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
25:08The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
21:48Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
32:05Poor expression levels, solubilization, and stability — these are the daily challenges that your membrane protein production team faces every day. You go through long cycles of expression optimization
25:16Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
25:01Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
28:21Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates.
14:01The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
12:06What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they're outside of their native environment. Just know
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
35:24SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out
33:11Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
22:36Hear how Dr. Sathya Venkataramani from Janssen Biotherapeutics maximized protein stability using the Prometheus in a real life case study about the design and characterization of antibody-based drugs.
29:22Learn about the causes of protein aggregation and how to implement the best solutions to enhance protein stability with Dr. John Carpenter from the University of Colorado. He presented as one of three
27:20Explore the complexities and drivers of molecular interactions with Dr. Tom Laue from the University of New Hampshire. He presented as a keynote speaker in the Protein Stability & Function: Can't have
42:46Join this case study and walk through of Prometheus Panta. Make your formulation workflow more efficient and effective with simultaneous, multi-parameter stability characterization. What you’ll lear
1:06:54Join this e-demo on the Prometheus Panta. Learn how to collect thermal unfolding, particle sizing, and aggregation data on a single platform using the NIST mAb. The growing complexity of therapeutic
34:16Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
38:40Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few
